Information on results of RFP - 024313B - BIOANALITYCAL METHOD DEVELOPMENT, DETERMINATION OF AD-O51.4 AND ANTI-DRUG ANTIBODY LEVEL IN SERUM OF PATIENTS ENROLLED IN THE CLINICAL TRIAL (GLP STANDARD)

In connection with co-financing the project "Clinical trial of the first phase (Ia/Ib) of a fusion protein with a dual anticancer mechanism", financed from the State budget by Medical Research Agency (no. 2022/ABM/05/00006-00), acting pursuant to §8 of the co-financing agreement, Adamed Pharma S.A. informs that the order will be awarded to Gdański Uniwersytet Medyczny, which submits the most advantageous offer.